Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders.

Lotan I, Charlson RW, Ryerson LZ, Levy M, Kister I.

Mult Scler Relat Disord. 2019 Dec 30;39:101920. doi: 10.1016/j.msard.2019.101920. [Epub ahead of print]

PMID:
31918241
2.

Nocturia in Patients With Multiple Sclerosis.

Peyronnet B, Krupp LB, Reynolds WS, Gamé X, Amarenco G, Cornu JN, Ryerson LZ, Sammarco CL, Howard JE, Charlson RW, Dmochowski RR, Brucker BM.

Rev Urol. 2019;21(2-3):63-73.

3.

Rituximab-induced serum sickness in multiple sclerosis patients.

Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E.

Mult Scler Relat Disord. 2019 Nov;36:101402. doi: 10.1016/j.msard.2019.101402. Epub 2019 Sep 17.

PMID:
31542710
4.

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.

Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, Goldberg JD, Li X, Riddle E, Smirnakis K, Kasliwal R, Ren Z, Hotermans C, Ho PR, Campbell N.

Neurology. 2019 Oct 8;93(15):e1452-e1462. doi: 10.1212/WNL.0000000000008243. Epub 2019 Sep 12.

PMID:
31515290
5.

Multiple sclerosis and sarcoidosis: A case for coexistence.

Tyshkov C, Pawate S, Bradshaw MJ, Kimbrough DJ, Chitnis T, Gelfand JM, Ryerson LZ, Kister I.

Neurol Clin Pract. 2019 Jun;9(3):218-227. doi: 10.1212/CPJ.0000000000000629.

PMID:
31341709

Supplemental Content

Loading ...
Support Center